ubiquitin protein ligase E3AGenealiases: ANCR · AS · E6-AP · EPVE6AP · HPVE6A · PIX1
Q-omics provides the consensus-scored UBE3A profile across patient tissues and cancer cell-line models. UBE3A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UBE3A is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, UBE3A RNA expression shows 20,743 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where UBE3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE3A survival associations across molecular data types. UBE3A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE3A RNA expression–survival associations across cancer types. High UBE3A expression shows unfavorable associations in UVM, ACC and PAAD, but favorable associations in KIRC, SCLC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UBE3A RNA expression.
This table summarizes UBE3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UBE3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE3A shows lower tumor expression in THCA and UCEC and higher tumor expression in LIHC, HNSC, CHOL and LUSC. The THCA box plot shows higher UBE3A RNA expression in normal versus tumor tissue (log2 FC = −0.488, t-test p < 0.001).
This table shows molecular features associated with UBE3A in patient tissues and cancer cell lines. In patient samples, UBE3A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
